Price
Target price
€11.38
€11.38
-1.310%
-0.15
-1.310%
€25.47
22:25 / Tradegate
WKN: A2AG6H / Symbol: NTLA / Name: Intellia / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Intellia Therapeutics Inc Stock
A loss of -1.310% shows a downward development for Intellia Therapeutics Inc.
Our community is currently high on Intellia Therapeutics Inc with 24 Buy predictions and 5 Sell predictions.
Based on the current price of 11.38 € the target price of 25 € shows a potential of 119.68% for Intellia Therapeutics Inc which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Intellia Therapeutics Inc stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "EBIT growth" there were negative voices in the community.
Pros and Cons of Intellia Therapeutics Inc in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
S********** s********
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Intellia Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Intellia Therapeutics Inc | -1.310% | -0.391% | -1.801% | 85.636% | 46.682% | -66.633% | -83.186% |
| Chromadex Corp | -2.060% | -2.591% | -10.900% | -39.355% | -31.636% | 170.601% | -52.405% |
| Cardio3 Biosciences S.A. | -2.140% | 0.000% | -18.841% | -43.205% | 107.407% | -65.389% | -95.205% |
| Polynovo Ltd | -7.020% | 14.000% | 1.786% | -12.308% | -16.176% | -47.222% | -67.429% |
Comments
Intellia Therapeutics (NTLA) was upgraded by JonesTrading from "hold" to "buy". They now have a $29.00 price target on the stock.
Show more
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics (NTLA) had its price target lowered by Canaccord Genuity Group Inc. from $54.00 to $48.00. They now have a "buy" rating on the stock.
Show more
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics (NTLA) had its "buy" rating reaffirmed by Brookline Capital Acquisition Corp..
Show more
Ratings data for NTLA provided by MarketBeat
News
This Cathie Wood Stock Is Up 47% This Year: Is It Too Late to Buy?
Cathie Wood, the CEO of the investment management firm Ark Invest, is known for focusing on companies with significant innovative potential. One of her firm's picks, Intellia Therapeutics (NASDAQ:
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Cathie Wood seems to always be making market moves. The founder and CEO of Ark Invest publishes her transactions at the end of every trading day, and that gives us all a great way to track one of
This Cathie Wood Stock Is Already Up 41% This Year, But Is It a Buy?
Cathie Wood, the CEO of Ark Invest, is known for investing in companies with strong innovative potential. That includes biotechs that specialize in gene editing, a group of techniques that could